Illumina Inc
NASDAQ:ILMN

Watchlist Manager
Illumina Inc Logo
Illumina Inc
NASDAQ:ILMN
Watchlist
Price: 134.95 USD -0.27% Market Closed
Market Cap: 20.6B USD

Intrinsic Value

The intrinsic value of one ILMN stock under the Base Case scenario is 133.65 USD. Compared to the current market price of 134.95 USD, Illumina Inc is Overvalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ILMN Intrinsic Value
133.65 USD
Overvaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Illumina Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about ILMN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ILMN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Illumina Inc.

Explain Valuation
Compare ILMN to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Intense competition from emerging long-read and single-molecule sequencing technologies could erode Illumina’s dominant market share, especially if newer platforms offer lower costs or superior accuracy that siphon demand from its core reagent and instrument sales.

Regulatory scrutiny tied to the Grail acquisition and potential antitrust setbacks may result in forced divestitures, significant legal expenses, or delays in integrating Grail’s liquid biopsy offerings into Illumina’s product portfolio, stalling strategic growth plans.

Weakness in external research funding—particularly from government grants—could reduce demand for Illumina’s high-throughput platforms, as budget-constrained labs prioritize lower-capacity instruments or postpone major capital expenditures.

Bull Theses

Illumina’s gold-standard position in next-generation sequencing underpins strong recurring revenues from instruments and consumables, supported by a large installed base that continually drives reagent demand and service contracts.

The accelerated shift toward personalized medicine and population genomics initiatives worldwide expands Illumina’s potential customer base, boosting both instrument placements and ongoing consumables usage for large-scale projects.

Illumina’s continued innovation in high-throughput and mid-throughput systems helps the company capture both premium and cost-sensitive segments, protecting margins and maintaining brand leadership against emerging competitors.

Show More Less
How do you feel about ILMN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Illumina Inc

Current Assets 2.8B
Cash & Short-Term Investments 1.3B
Receivables 751m
Other Current Assets 767m
Non-Current Assets 3.4B
Long-Term Investments 273m
PP&E 1.1B
Intangibles 1.3B
Other Non-Current Assets 640m
Current Liabilities 2B
Accounts Payable 218m
Accrued Liabilities 428m
Other Current Liabilities 1.3B
Non-Current Liabilities 1.8B
Long-Term Debt 994m
Other Non-Current Liabilities 840m
Efficiency

Free Cash Flow Analysis
Illumina Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Illumina Inc

Revenue
4.3B USD
Cost of Revenue
-1.4B USD
Gross Profit
2.9B USD
Operating Expenses
-2B USD
Operating Income
875m USD
Other Expenses
-172m USD
Net Income
703m USD
Fundamental Scores

ILMN Profitability Score
Profitability Due Diligence

Illumina Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
ROE is Increasing
ROIC is Increasing
Exceptional Gross Margin
52/100
Profitability
Score

Illumina Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

ILMN Solvency Score
Solvency Due Diligence

Illumina Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Low D/E
High Altman Z-Score
Negative Net Debt
Long-Term Solvency
57/100
Solvency
Score

Illumina Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ILMN Price Targets Summary
Illumina Inc

Wall Street analysts forecast ILMN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ILMN is 126.28 USD with a low forecast of 80.8 USD and a high forecast of 204.75 USD.

Lowest
Price Target
80.8 USD
40% Downside
Average
Price Target
126.28 USD
6% Downside
Highest
Price Target
204.75 USD
52% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Illumina Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ILMN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ILMN Insider Trading
Buy and sell transactions by insiders

ILMN News

Other Videos
What is the Intrinsic Value of one ILMN stock?

The intrinsic value of one ILMN stock under the Base Case scenario is 133.65 USD.

Is ILMN stock undervalued or overvalued?

Compared to the current market price of 134.95 USD, Illumina Inc is Overvalued by 1%.

Back to Top